Oncotelic Therapeutics CBO Saund Saran received a grant of 1,500 restricted stock units on July 10, 2026. Each RSU represents a contingent right to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, for up to 1,500,000 common shares if fully vested and converted. The RSUs are subject to performance and time-based vesting tied to an uplisting of the company’s common stock to a national securities exchange and continued service requirements.
Shah Amit B. reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics CFO Amit B. Shah received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, which is itself convertible into common stock, if performance and time-based vesting conditions tied to a national-exchange uplisting are satisfied.
Trieu Vuong reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics reports that Chairman and CEO Trieu Vuong received a grant of 2,000 restricted stock units on July 10, 2026. Each RSU can settle into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, subject to performance- and time-based vesting. The RSUs vest only if the company uplists its common stock to a national securities exchange by June 30, 2027 (or a later board-approved date) and Vuong remains in service for six months after uplisting. After these reported holdings, Vuong owns 94,124,319 common shares directly and holds additional shares indirectly, including 6,872,529 through his spouse and 16,780,384 through Autotelic Inc.
Oncotelic Therapeutics, Inc. Chairman and CEO Dr. Vuong Trieu reported an open-market purchase of company stock. On July 1, 2026, he bought 240,000 shares of Common Stock at a price of $0.0431 per share in his individual capacity.
Following this transaction, Dr. Trieu directly owned 94,124,319 shares of Common Stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc., providing a view of both his direct and indirect ownership stakes.
Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a convertible promissory note with an aggregate gross principal amount of $178,410. The note carries a 12% original issue discount, bears interest at 12% per year, and matures on the earlier of one year from the agreement date, an acceleration after an Event of Default, or full prepayment.
The note is convertible into common stock at the lower of a fixed $0.06 per share or 85% of the lowest traded price over the 10 trading days before conversion, subject to adjustments. Oncotelic also issued 500,000 shares of common stock to Pacific Pier as commitment shares. If an Event of Default occurs, the principal and accrued interest become immediately due in cash at a 16% default interest rate. The note and shares were issued in a private offering relying on the Section 4(a)(2) exemption from Securities Act registration.
Oncotelic Therapeutics, Inc. director, chairman, CEO and ten percent owner Vuong Trieu reported open-market purchases of a total of 255,000 shares of common stock at $0.045 per share over three days in late June 2026. He bought 65,000 shares on June 22, 75,000 shares on June 23, and 115,000 shares on June 24 in his individual capacity. Following these purchases, his directly held stake rose to 93,884,319 shares. The filing also lists additional indirect holdings of common stock, including 6,872,529 shares held by his spouse and 16,780,384 shares held by Autotelic Inc. as of June 22.
Oncotelic Therapeutics, Inc. CFO Amit B. Shah bought additional company stock in the open market. On June 22, 2026, he purchased 20,000 shares of common stock at a price of $0.05 per share in his individual capacity. Following this transaction, he directly owns 378,837 shares of Oncotelic common stock.
Oncotelic Therapeutics, Inc. Chairman and CEO Vuong Trieu reported open-market purchases of company common stock. On June 15, 2026, he bought 96,000 shares at $0.05 per share, and on June 17, 2026, he bought 239,759 shares at $0.0446 per share.
After these transactions, his directly held stake is reported as 93,629,319 shares of common stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held through Autotelic Inc., providing a view of both his direct and related-entity ownership.
Oncotelic Therapeutics’ quarter ended March 31, 2026 shows a small cash position and continued losses alongside a very large non‑cash investment asset. Cash was $63,614 with $20,000 in restricted cash, while the company reported a net loss of $2,193,776, wider than a year earlier.
Total assets were $393,955,039, driven mainly by a Level 3 fair value investment in GMP Bio of $388,000,000 and related deferred tax liability of $111,550,000. Stockholders’ equity was $262,211,541 and total liabilities were $131,743,498, but working capital was negative by about $16.3 million.
Management states there is substantial doubt about the company’s ability to continue as a going concern due to recurring losses, limited funding and negative operating cash flow of about $0.3 million for the quarter. To address this, the company has layered convertible debt, including a new ~${398,333} Mast Hill note, and access to a Mast Hill equity purchase agreement for up to $25 million.
Operationally, the JV with Dragon and GMP Bio continues to prepare Phase 2 and 3 trials for OT‑101 and advance five additional nanoparticle cancer therapies. In March 2026, Oncotelic also signed a joint development, manufacturing and licensing agreement with TechForce Robotics to build AI‑enabled, GMP‑compliant robotic systems for pharmaceutical manufacturing.
Oncotelic Therapeutics, Inc. completed a patent-focused merger and related IP restructurings with Lunai Bioworks and affiliates. A holding company owning a multi‑jurisdictional patent portfolio was merged into a Lunai subsidiary, and Lunai issued eight shares of Series B Convertible Preferred Stock with an aggregate Stated Value of $20,000,000 to Oncotelic and Pelerin.
Oncotelic received five preferred shares with a stated value of $12,500,000 and a perpetual, royalty‑free, exclusive license to exploit the transferred intellectual property in all fields except defined biodefense and Alzheimer’s disease indications. Separately, Autotelic Inc. transferred additional drug and delivery platform assets to Oncotelic in exchange for equity equal to ten percent of Oncotelic’s fully diluted shares, issuable upon a future NYSE/NASDAQ uplisting. Both the merger consideration and the asset transfer were non‑cash transactions and rely on contracts attached as exhibits.